This article is more than 5 years old. Information may no longer be current.

VIDEO: Gemelli Biotech launches IBS blood test at ACG

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

PHILADELPHIA — In this exclusive video perspective from the American College of Gastroenterology Annual Meeting, Matt Mitcho, CEO of Gemelli Biotech, talks about the company’s new partnership with Cedars-Sinai, IBS Smart.

“We’re here at ACG to launch IBS Smart, a second-generation blood test to diagnose patients with IBS-D and IBS-M,” Mitcho told Healio Gastroenterology and Liver Disease. “IBS Smart looks at levels of anti-vinculin and anti-CDTB which are important biomarkers for patients with IBS.”

Mitcho said the partnership with the Medically Associated Science and Technology Program at Cedars Sinai Medical Center allows Gemelli to get a first look at cutting edge science that comes out of the program. IBS Smart is exclusively licensed by the MAST program to Gemelli.

Disclosure: Mitcho is employed by Gemelli.